infecti
diseas
continu
plagu
mankind
evolv
keep
pace
effort
control
sir
william
osler
captur
ongo
fear
infecti
pathogen
said
human
three
great
enemi
fever
famin
war
far
greatest
far
terribl
fever
despit
signific
impact
antimicrobi
vaccin
public
health
one
major
human
pathogen
eradicatedvariola
viru
agent
smallpox
place
seri
new
reemerg
microb
respons
isol
infect
region
outbreak
global
pandem
bacteri
fungal
parasit
pathogen
capac
caus
widespread
epidem
black
death
caus
yersinia
pesti
centuri
europ
howev
bacteria
fungi
parasit
less
like
caus
widespread
human
pandem
point
histori
less
amen
vaccin
strategi
viral
diseas
focus
virus
catalogu
newli
discov
human
pathogen
begin
centuri
show
predict
nearli
linear
rate
new
agent
discov
time
howev
viru
famili
associ
human
infect
number
seem
plateau
chapter
concentr
vaccin
emerg
viral
diseas
experi
last
decad
hiv
sar
ebola
taught
us
potenti
consequ
viral
infecti
threat
global
health
econom
polit
stabil
emerg
viral
infect
pandem
potenti
chronic
persist
acut
natur
dissemin
respiratori
droplet
bodili
fluid
emerg
anim
reservoir
spread
via
insect
vector
precipit
chang
climat
anim
habitat
human
popul
dynam
ecolog
event
emerg
consequ
human
activ
context
deliber
viral
modif
form
biowarfar
face
import
question
includ
done
anticip
event
best
prepar
interven
new
chang
viral
threat
arriv
current
licens
antivir
vaccin
util
liveattenu
wholeinactiv
virus
although
exampl
effect
viruslik
particl
vlp
vaccin
set
new
pandem
viral
threat
without
advantag
preexist
understand
pathogenesi
growth
attenu
featur
would
difficult
quickli
develop
tradit
liveattenu
wholeinactiv
vaccin
approach
due
uncertainti
safeti
attenu
mutat
product
replicationcompet
viru
bulk
therefor
like
develop
vaccin
emerg
infect
involv
new
technolog
yet
licens
human
use
use
technolog
provid
candid
vaccin
base
inform
deriv
entir
target
gene
sequenc
safer
expediti
procedur
requir
viru
isol
growth
requir
high
level
contain
therefor
even
viru
famili
current
licens
vaccin
addit
approach
beyond
liveattenu
wholeinactiv
product
also
pursu
histor
decad
elaps
new
viru
discov
relev
vaccin
becom
avail
human
use
fig
set
epidem
protract
vaccin
develop
timelin
incompat
rapid
deploy
vaccin
intervent
therefor
practic
consider
immedi
control
outbreak
part
west
african
ebola
outbreak
emerg
new
viral
threat
public
health
becom
global
concern
media
polit
visibl
fortun
time
remark
technic
advanc
human
monoclon
antibodi
discoveri
structureguid
antigen
design
nucleic
acid
sequencingmak
rapid
develop
biolog
feasibl
therefor
defin
new
approach
pathway
effici
deploy
vaccin
intervent
emerg
infect
prioriti
public
health
agenc
commerci
entiti
govern
offici
nonprofit
organ
howev
key
rapid
vaccin
respons
advanc
prepar
sever
step
need
improv
prepared
emerg
viral
infecti
diseas
divid
broad
categori
surveil
discoveri
reagent
assay
anim
model
develop
vaccin
design
product
develop
manufactur
clinic
evalu
appropri
regulatori
framework
depend
featur
viru
structur
transmiss
dynam
entri
requir
tropism
replic
strategi
vaccin
approach
propos
design
evalu
small
anim
immunogen
protect
challeng
manufactur
candid
vaccin
immedi
market
pose
signific
dilemma
stage
advanc
vaccin
develop
carri
larg
pharmaceut
compani
need
make
profit
stay
busi
emerg
infecti
diseas
pose
public
health
threat
rare
present
compel
commerci
opportun
vaccin
requir
larg
invest
histor
rel
low
probabl
success
without
extens
iter
process
evalu
redesign
therefor
addit
new
biolog
tool
need
polit
priorit
public
fund
advanc
vaccin
develop
new
busi
model
manag
process
review
describ
vaccin
develop
effort
three
distinct
virus
collect
captur
mani
challeng
face
develop
vaccin
emerg
viral
threat
ebola
member
filovirida
famili
spread
bodi
fluid
secret
rel
low
attack
rate
caus
system
diseas
high
mortal
chikungunya
alphaviru
figur
time
identif
viral
pathogen
vaccin
avail
vaccin
develop
lengthi
process
often
measur
decad
mani
step
requir
even
tradit
empir
approach
includ
identif
target
antigen
assay
develop
defin
seropreval
incid
relev
popul
understand
transmiss
dynam
whether
intermedi
anim
host
develop
anim
model
explor
pathogenesi
defin
immun
mechan
protect
design
vaccin
antigen
determin
formul
deliveri
rout
method
preclin
evalu
safeti
immunogen
manufactur
sever
year
clinic
evalu
clear
regulatori
hurdl
vaccin
fail
step
rare
first
attempt
concept
becom
final
product
togavirida
famili
transmit
mosquito
vector
high
attack
rate
caus
system
diseas
low
mortal
high
frequenc
chronic
disabl
arthriti
middl
east
respiratori
syndrom
mer
cov
betacoronaviru
member
coronavirida
famili
spread
respiratori
droplet
caus
rel
high
mortal
person
underli
diseas
reproduct
rate
r
persontoperson
spread
occasion
superspread
infect
multipl
peopl
mer
reservoir
dromedari
camel
continu
sourc
new
human
infect
ebola
chikungunya
mer
cov
repres
infecti
pathogen
pandem
potenti
use
new
technolog
arriv
comprehens
understand
viral
structur
pathogenesi
pave
way
ration
vaccin
design
virus
herein
elabor
iter
path
taken
develop
evalu
candid
vaccin
ebola
chikungunya
mer
cov
factor
propel
delay
progress
focu
discuss
primarili
candid
vaccin
develop
niaid
vaccin
research
center
necessarili
promis
advanc
familiar
event
associ
develop
factor
impact
advanc
implement
ebola
highli
virul
pathogen
famili
filovirida
ebolaviru
envelop
negativestrand
rna
viru
whose
genom
encod
structur
protein
includ
transmembran
glycoprotein
mediat
viral
entri
host
cell
surfac
glycoprotein
gp
mediat
viral
attach
entri
primari
antigen
target
vaccin
develop
five
speci
ebola
identifi
includ
zair
caus
west
african
epidem
sudan
bundibugyo
tai
forest
reston
ebola
viru
diseas
evd
first
recogn
two
distinct
outbreak
ebola
river
valley
democrat
republ
congo
formerli
zair
sudan
evd
emerg
gabon
outbreak
involv
peopl
kikwit
democrat
republ
congo
drc
sinc
sporad
outbreak
occur
equatori
africa
especi
drc
republ
congo
gabon
uganda
sudan
fatal
rate
averag
incub
period
day
onset
evd
manifest
fever
chill
malais
myalgia
onset
gastrointestin
symptom
includ
nausea
vomit
diarrhea
day
fatal
death
typic
occur
day
character
hypovolem
shock
multiorgan
failur
diseas
transmit
humantohuman
direct
contact
infect
bodili
fluid
mucos
surfac
break
skin
mar
guinea
ministri
health
notifi
highli
pathogen
febril
ill
circul
guecked
macenta
epidemiolog
evalu
ensu
sampl
hospit
patient
sent
lab
franc
germani
ebola
confirm
either
polymeras
chain
reaction
pcr
electron
microscopi
isol
cell
cultur
viral
rna
extract
sequenc
compar
avail
ebola
sequenc
genbank
enabl
phylogenet
analysi
ebola
strain
identifi
similar
previous
collect
ebola
strain
drc
gabon
turn
outbreak
trace
singl
index
case
boy
die
dec
guecked
epidem
evd
follow
account
case
prior
evd
outbreak
combin
jul
suspect
confirm
case
death
report
major
case
occur
west
african
countri
guinea
liberia
sierra
leon
world
health
organ
declar
epidem
public
health
emerg
intern
concern
aug
outbreak
emerg
intern
commun
respond
unpreced
effort
acceler
ebola
vaccin
develop
prior
largest
singl
ebola
outbreak
infect
lead
death
vaccin
research
center
within
nation
institut
allergi
infecti
diseas
perform
seri
phase
clinic
trial
evalu
safeti
immunogen
gp
antigen
construct
includ
dna
vaccin
encod
transmembranedelet
secret
version
glycoprotein
recombin
human
adenoviru
serotyp
vector
vaccin
encod
ebola
gp
one
amino
acid
mutat
subsequ
dna
vaccin
encod
fulllength
wildtyp
wt
gp
phase
studi
show
wt
fulllength
gp
safe
well
toler
parallel
studi
defin
immunolog
correl
protect
optim
antigen
deliveri
approach
evalu
nonhuman
primat
nhp
addit
import
role
antibodi
target
gp
found
cellmedi
immun
found
critic
vaccin
efficaci
nhp
also
found
antivector
immun
would
diminish
vaccin
potenc
particularli
induct
cell
high
seropreval
rare
serotyp
adenoviru
vector
explor
includ
human
vector
chimpanzeederiv
rad
vector
chimpanze
adenoviru
serotyp
abbrevi
encod
wildtyp
glycoprotein
ebola
zair
sudan
speci
ultim
chosen
candid
vaccin
vector
low
seropreval
similar
potenc
pattern
innat
immun
respons
induct
vector
origin
produc
okairo
own
glaxosmithklin
gsk
vector
potenc
compar
consid
import
rapid
induct
antibodi
cell
singl
dose
would
facilit
use
gp
vaccin
outbreak
set
use
ring
vaccin
strategi
achiev
rapid
short
term
protect
highest
risk
infect
zair
sudan
gp
includ
initi
vaccin
protect
zair
sudan
common
speci
respons
evd
replicationdefect
vaccin
call
provid
protect
nonhuman
primat
week
follow
vaccin
otherwis
lethal
ebola
challeng
model
partial
protect
lethal
challeng
month
follow
vaccin
also
shown
effect
prime
modifi
vaccinia
viru
ankara
mva
vector
vaccin
boost
encod
glycoprotein
insert
improv
surviv
lethal
ebola
challeng
postboost
combin
primeboost
produc
much
higher
magnitud
respons
might
provid
durabl
protect
health
care
worker
ambul
driver
burial
worker
other
ongo
risk
ebola
exposur
first
quarter
target
phase
clinic
evalu
nih
clinic
center
preinvestig
new
drug
ind
applic
submit
end
aug
howev
respons
epidem
nih
fda
irb
other
coordin
effort
consolid
timelin
ind
applic
submit
fda
aug
phase
trial
began
day
later
vaccin
found
safe
immunogen
earli
phase
test
two
dose
particl
unit
pu
day
postvaccin
result
publish
month
later
vaccin
recipi
develop
glycoprotein
gp
specif
antibodi
howev
gpspecif
antibodi
respons
well
gpspecif
cell
respons
greater
pu
dose
antibodi
titer
higher
dose
rang
associ
protect
immun
nhp
challeng
model
zair
gp
antigen
encod
deriv
origin
mayinga
strain
ebola
isol
compar
strain
circul
west
africa
differ
gp
residu
outsid
glycan
cap
cleav
prior
viru
entri
mayinga
also
relat
genet
outbreak
strain
kikwit
strain
use
nhp
challeng
studi
therefor
avail
ebola
zair
construct
thought
antigen
relev
outbreak
strain
suitabl
test
directli
address
west
african
crisi
acceler
manufactur
timelin
addit
phase
studi
vaccin
monoval
form
encod
gp
zair
sudan
speci
perform
unit
state
unit
kingdom
mali
switzerland
dose
rang
studi
done
collabor
gsk
support
advanc
monoval
vaccin
ongo
phase
iiiii
studi
liberia
well
us
evalu
primeboost
regimen
consist
follow
mvaeboz
evalu
durabl
immun
respons
monoval
also
evalu
prime
boost
recombin
mva
vector
provid
bavarian
nordic
express
gp
zair
sudan
marburg
n
tai
forest
site
unit
kingdom
mali
similar
vaccin
approach
use
prime
mva
boost
develop
crucel
own
janssen
part
johnson
johnson
evalu
subsequ
clinic
trial
parallel
develop
replicationcompet
recombin
vesicular
stomat
viru
rvsv
vaccin
express
gp
ebola
zair
kikwit
strain
show
promis
result
preclin
nhp
challeng
model
vaccin
develop
public
health
agenc
canada
licens
bioprotect
system
subsidiari
newlink
genet
subsequ
licens
merck
donat
vial
vaccin
canadian
govern
enabl
initi
evalu
candid
vaccin
peopl
dose
rang
million
pfu
phase
trial
gabon
kenya
germani
switzerland
although
lifethreaten
advers
event
observ
evid
unexpect
viral
seed
joint
transient
arthriti
addit
vaccin
viru
posit
skin
vesicl
particip
lower
dose
rvsvzebov
pfu
im
diminish
likelihood
rvsv
infect
peripher
tissu
thirteen
particip
develop
arthriti
particip
develop
cutan
lymphocyt
vascul
rvsv
establish
etiolog
base
synovi
fluid
skin
lesion
analysi
vaccin
immunogen
vaccin
recipi
evalu
develop
gpspecif
antibodi
respons
addit
evalu
candid
vaccin
two
phase
trial
unit
state
wrair
nih
support
advanc
vaccin
million
pfu
dose
compar
million
pfu
dose
million
pfu
result
higher
igg
neutral
antibodi
titer
higher
dose
vaccin
current
evalu
niaidsponsor
prevail
trial
liberia
cdcsponsor
strive
studi
sierra
leon
whosponsor
ebola
suffit
studi
guinea
notabl
skin
joint
complic
seen
activ
followup
individu
unit
state
african
studi
interim
result
ebola
suffit
phase
iii
trial
evalu
safeti
efficaci
rvsvzebov
unblind
clusterrandom
trial
guinea
encourag
consist
vaccin
efficaci
trial
util
ring
vaccin
design
individu
high
risk
infect
contact
contactsofcontact
lab
confirm
case
evd
random
cluster
receiv
either
immedi
vaccin
rvsvzebov
delay
vaccin
day
later
case
evd
symptom
onset
day
follow
random
group
receiv
immedi
vaccin
cluster
subject
wherea
author
report
case
evd
subject
random
delay
vaccin
cluster
subject
pathway
licensur
new
vaccin
requir
evid
vaccin
safeti
efficaci
clinic
trial
infecti
pathogen
emerg
sporad
low
incid
ebola
abil
perform
random
placebocontrol
doubleblind
efficaci
trial
remain
limit
factor
hard
fought
declin
evd
case
west
africa
welcom
hope
lead
complet
control
epidem
without
rebound
reemerg
howev
declin
like
preclud
effort
evalu
vaccin
efficaci
vaccin
candid
outbreak
vaccin
remain
unknown
path
licensur
feasibl
absenc
human
efficaci
data
regul
need
consid
support
evid
preclin
nhp
challeng
model
safeti
data
ongo
human
trial
use
altern
surrog
immunogen
endpoint
adequ
move
forward
licens
therefor
sever
challeng
question
remain
regul
vaccin
develop
alik
includ
determin
ebola
vaccin
made
avail
next
ebola
epidem
trial
design
use
ie
ring
vaccin
strategi
delay
commun
random
stepwedg
design
stage
vaccin
placebocontrol
random
studi
whether
initi
result
recent
trial
preclud
evalu
experiment
unlicens
product
nonetheless
sever
import
lesson
extract
recent
develop
ebola
vaccin
candid
perhap
import
rapid
develop
test
candid
vaccin
made
possibl
year
prior
invest
studi
ebola
basic
virolog
pathogenesi
part
driven
biodefens
concern
factor
enabl
acceler
vaccin
develop
includ
preexist
establish
anim
model
preclin
data
nhp
challeng
studi
presenc
cgmp
vaccin
product
global
concern
extens
media
coverag
polit
visibl
help
foster
coordin
fund
agenc
regulatori
author
govern
clinic
trial
site
laboratori
commerci
partner
publish
chikungunya
viru
chikv
mosquitoborn
alphaviru
famili
togavirida
transmit
primarili
aed
aegypti
aed
albopictu
mosquito
three
chikv
clade
identifi
includ
west
african
asian
eastcentralsouth
african
share
signific
amino
acid
homolog
chikungunya
infect
manifest
abrupt
onset
fever
myalgia
rash
headach
nausea
arthralgia
ill
onset
typic
day
follow
viral
transmiss
hallmark
arthriti
chikv
infect
relaps
incapacit
may
persist
month
sever
manifest
chikungunya
includ
myocard
hepat
neurolog
complic
includ
enceph
although
rare
death
occur
particularli
elderli
infant
current
fda
licens
vaccin
treatment
specif
chikungunya
chikv
kb
singlestrand
positivesens
rna
genom
encod
nonstructur
protein
involv
viru
replic
structur
protein
includ
capsid
envelop
glycoprotein
glycoprotein
mediat
cell
fusion
glycoprotein
interact
host
receptor
matur
virion
diamet
nm
extern
surfac
exhibit
trimer
spike
consist
heterodim
chikungunya
viru
discov
east
african
virolog
research
institut
entebb
uganda
uganda
virolog
institut
uvri
isol
member
makond
tribe
tanzania
earli
chikv
respons
outbreak
africa
asia
sinc
chikv
endem
tropic
subtrop
region
africa
exist
part
enzoot
cycl
howev
intermitt
epidem
emerg
character
humanmosquitohuman
transmiss
attack
rate
exceed
aegypti
eastcentralsouth
african
ecsa
strain
recent
detect
brazil
may
make
adapt
albopictu
like
occur
broader
spread
north
america
possibl
chikv
viremia
peak
day
symptom
onset
titer
reach
viral
rna
copiesml
neutral
activ
induct
antibodi
isotyp
earli
cours
infect
associ
lower
risk
chronic
diseas
persist
arthralgia
research
date
support
antibodymedi
mechan
protect
chikv
infect
passiv
protect
shown
otherwis
lethal
mous
model
chikv
infect
follow
igg
administr
nhp
receiv
chikungunya
viruslik
particl
vlp
vaccin
sever
promis
candid
vaccin
platform
evalu
includ
formalininactiv
chikv
vaccin
recombin
mva
measl
vector
vaccin
chimer
alphaviru
vaccin
insect
cellproduc
vlp
vaccin
candid
dna
vaccin
candid
live
attenu
chikv
vaccin
advanc
phase
ii
test
induc
neutral
antibodi
chikv
day
recipi
also
associ
arthralgia
subject
due
familiar
limit
obstacl
advanc
candid
vaccin
develop
niaid
vaccin
research
center
focu
discuss
primarili
mammalian
cellproduc
vlp
vaccin
candid
vaccin
evalu
phase
clinic
trial
current
advanc
phase
ii
clinic
test
produc
vlp
akahata
cowork
transfect
hek
cell
express
vector
encod
protein
west
african
chikv
strain
electron
microscopi
reveal
product
vlp
morpholog
appear
wildtyp
chikv
character
nm
extern
diamet
nm
core
diamet
structur
glycoprotein
organ
heterodim
glycoprotein
spike
preclin
assess
nhp
receiv
vlp
develop
neutral
antibodi
heterolog
homolog
chikv
strain
challeng
model
nhp
protect
viremia
well
postinflammatori
sequela
infect
expos
intraven
chikv
challeng
week
vlp
administr
vlp
vaccin
candid
found
safe
immunogen
phase
doseescal
clinic
trial
evalu
dose
rang
dose
regimen
week
healthi
adult
neutral
antibodi
outbreak
strain
ecsa
clade
identifi
particip
week
follow
second
vaccin
reveal
robust
immunogen
evid
crossreact
neutral
activ
sever
advantag
vlp
vaccin
includ
highli
symmetr
exterior
resembl
wildtyp
viru
induct
high
titer
neutral
antibodi
safeti
profil
nonrepl
candid
vaccin
low
contain
manufactur
factor
contribut
delay
advanc
develop
vaccin
includ
difficulti
establish
commerci
partnership
resourc
need
process
develop
scaleup
difficulti
establish
clinic
trial
infrastructur
defin
efficaci
immun
correl
protect
due
ongo
chikungunya
epidem
america
caribbean
opportun
obtain
efficaci
result
field
trial
therefor
advanc
clinic
evalu
candid
vaccin
public
health
imper
field
trial
delay
outbreak
satur
region
diseas
becom
sporad
difficult
ever
obtain
efficaci
outcom
establish
immunolog
correl
protect
complic
achiev
licensur
gener
use
anoth
exampl
public
option
manufactur
would
facilit
develop
vaccin
emerg
infecti
diseas
coronavirus
envelop
singlestrand
positivesens
rna
virus
larg
genom
kb
endem
human
coronavirus
widespread
includ
coronavirus
gener
caus
mild
respiratori
infect
includ
common
cold
howev
sever
featur
coronavirus
allow
adapt
new
host
ecolog
nich
includ
larg
rna
genom
high
frequenc
rna
recombin
infidel
rnadepend
rna
polymeras
follow
emerg
sever
acut
respiratori
syndrom
coronaviru
sar
cov
highli
pathogen
lineag
b
betacoronaviru
concern
aros
novel
coronavirus
could
repres
major
public
health
threat
valid
emerg
middl
east
respiratori
syndrom
coronaviru
mer
cov
first
case
mer
cov
report
male
saudi
arabia
acut
pneumonia
subsequ
die
progress
pulmonari
renal
failur
subsequ
rapid
intern
respons
emerg
mer
cov
includ
genom
sequenc
develop
diagnost
assay
surveil
zoonot
reservoir
develop
anim
model
evalu
viral
pathogenesi
enabl
ration
design
candid
vaccin
complet
genom
sequenc
implic
coronaviru
rapidli
identifi
made
avail
genbank
genom
sequenc
enabl
phylogenet
taxonom
analysi
mer
cov
identifi
lineag
c
betacoronaviru
distinct
previous
known
human
coronavirus
close
relat
coronavirus
previous
isol
bat
clinic
present
mer
cov
rang
asymptomat
sever
respiratori
ill
culmin
death
follow
incub
period
day
day
present
symptom
includ
fever
cough
dyspnea
rapid
deterior
respiratori
statu
occur
within
day
symptom
onset
fatal
rate
estim
sinc
labconfirm
case
mer
cov
infect
least
death
global
includ
outbreak
individu
south
korea
initi
singl
index
case
man
return
trip
saudi
arabia
outbreak
seoul
primarili
restrict
hospit
set
individu
superspread
account
major
infect
patient
health
care
provid
mer
cov
express
membraneanchor
trimer
spike
protein
consist
subunit
engag
receptor
host
cell
subunit
mediat
membran
fusion
receptor
bind
domain
serv
primari
antigen
target
vaccin
develop
similar
angiotensinconvert
enzym
peptidas
receptor
use
sar
cov
mer
cov
target
cell
receptor
dipeptidyl
peptidas
amino
acid
type
ii
transmembran
glycoprotein
express
epitheli
endotheli
cell
sever
organ
includ
lung
kidney
shown
biomark
express
asthma
associ
glycem
homeostasi
microvascular
complic
diabet
transfect
human
otherwis
nonsuscept
cell
felin
murin
canin
speci
enabl
mer
cov
infect
lu
et
al
subsequ
solv
crystal
structur
receptor
bind
domain
complex
compar
serolog
studi
emerg
shortli
mer
cov
first
identifi
look
zoonot
reservoir
evalu
serumspecif
igg
target
receptorbind
subunit
perform
protein
microarray
confirm
viru
neutral
test
reveal
hightit
neutral
antibodi
preval
camel
experiment
support
camel
zoonot
reservoir
perform
adney
cowork
inocul
camel
mer
cov
camel
subsequ
develop
upper
respiratori
symptom
show
evid
upper
respiratori
tract
viral
shed
nasal
secret
day
postinocul
evid
zoonot
transmiss
camel
human
support
patient
die
mer
cov
follow
exposur
camel
rhinorrhea
nasal
swab
patient
camel
posit
mer
cov
rna
subsequ
genom
sequenc
reveal
isol
ident
howev
case
mer
cov
infect
link
camel
exposur
addit
studi
need
defin
transmiss
dynam
intermedi
host
low
herd
immun
human
highli
pathogen
viru
evid
zoonot
humantohuman
transmiss
suggest
outbreak
mer
cov
continu
occur
may
pandem
potenti
current
fda
approv
vaccin
mer
cov
previou
vaccin
develop
effort
sar
cov
creat
foundat
mer
cov
vaccin
design
sar
spike
protein
similarli
respons
receptor
bind
membran
fusion
primari
antigen
target
neutral
antibodi
vaccin
develop
candid
mer
cov
vaccin
also
target
spike
protein
approach
includ
subunit
protein
dna
genebas
vector
recombin
modifi
vaccinia
viru
ankara
vaccin
express
full
length
mer
cov
spike
protein
produc
neutral
antibodi
immun
mice
subsequ
cowork
focus
receptor
bind
domain
rbd
mer
cov
spike
protein
develop
subunit
protein
vaccin
five
differ
receptor
bind
domain
fragment
individu
fuse
fc
human
igg
evalu
receptor
bind
affin
antigen
immunogen
neutral
potenti
fragment
contain
stabli
fold
rbd
highest
affin
induc
highest
titer
neutral
antibodi
mice
immun
rabbit
minim
exposur
nonneutr
epitop
addit
two
recombin
vaccin
candid
develop
use
either
baculovirusbas
express
system
venezuelan
equin
enceph
replicon
particl
approach
potent
neutral
induc
mice
nhp
follow
immun
dna
express
fulllength
spike
protein
follow
boost
subunit
glycoprotein
strategi
elicit
respons
rbd
nonrbd
neutral
epitop
may
decreas
chanc
escap
mutat
dna
primeprotein
boost
regimen
provid
protect
computer
tomographi
ct
defin
pneumonia
nhp
viral
challeng
model
work
highlight
import
develop
mab
vaccin
target
antigen
order
defin
mechan
viral
neutral
protein
structur
antigen
guid
ration
vaccin
design
dna
plasmidbas
vaccin
encod
full
length
consensu
mer
spike
protein
construct
base
avail
protein
genom
sequenc
genbankncbi
databas
vaccin
induc
polyfunct
cell
humor
respons
mice
nhp
includ
antigenspecif
neutral
antibodi
mice
macaqu
camel
vaccin
also
provid
protect
pneumonia
nhp
viral
challeng
model
clinic
trial
data
yet
candid
mer
cov
vaccin
mer
cov
like
continu
caus
sporad
outbreak
fuel
camel
exposur
occasion
superspread
event
howev
rel
low
r
suggest
mer
cov
rel
low
probabl
caus
widespread
pandem
therefor
target
popul
vaccin
avail
gener
popul
group
high
risk
exposur
anim
reservoir
health
care
worker
endem
region
possibl
atrisk
travel
rel
small
market
difficult
commerci
organ
invest
mer
cov
vaccin
develop
low
incid
field
studi
evalu
efficaci
larg
difficult
complet
therefor
question
rais
achiev
advanc
develop
licens
vaccin
type
emerg
viru
activ
need
prepar
futur
pandem
viral
threat
includ
broad
spectrum
disciplin
skill
set
rang
logist
commun
epidemiolog
ecolog
clinic
trial
highli
technic
biomed
research
program
fortun
rel
recent
technolog
advanc
made
prospect
comprehens
program
systemat
prepar
emerg
infecti
diseas
feasibl
done
forethought
develop
program
would
strengthen
exist
health
care
program
build
research
infrastructur
significantli
improv
statu
global
public
health
particular
take
advantag
new
technolog
high
throughput
sequenc
isol
human
monoclon
antibodi
structur
biolog
atomiclevel
antigen
design
molecular
biolog
vector
biolog
tool
provid
inform
need
rapid
achiev
optim
express
immunogen
product
deliveri
vaccin
antigen
new
emerg
threat
like
current
crisi
caus
zika
viru
fig
due
new
technolog
avail
surveil
assay
develop
vaccin
design
anim
model
manufactur
scientif
aspect
vaccin
develop
limit
abil
prepar
emerg
viral
diseas
major
factor
need
address
includ
polit
provid
resourc
necessari
conduct
epidemiolog
laboratori
work
need
support
vaccin
develop
new
busi
model
creat
infrastructur
advanc
vaccin
develop
requir
profit
motiv
creativ
regulatori
process
clinic
trial
design
evalu
product
efficaci
outbreak
natur
sporad
caus
social
chao
importantli
achiev
solid
efficaci
data
support
licensur
critic
product
readili
avail
futur
epidem
novel
approach
vaccin
design
may
significantli
shorten
vaccin
develop
timelin
increas
frequenc
success
new
technolog
rapidli
evolv
last
year
make
atom
level
antigen
design
feasibl
provid
mechan
rapid
iter
improv
antigen
immunogen
candid
vaccin
particular
high
throughput
sequenc
provid
start
point
vaccin
antigen
help
defin
extent
genet
variabl
rel
inexpens
gene
synthesi
eas
isol
character
human
monoclon
antibodi
mab
target
antigen
abil
defin
structur
vaccin
antigen
complex
mab
desir
function
properti
develop
assay
evalu
immunogen
vaccin
anim
model
provid
foundat
rapid
develop
highli
character
candid
vaccin
advanc
clinic
evalu
figur
illustr
step
taken
case
mer
cov
rapidli
develop
tool
need
gener
candid
vaccin
advanc
knowledg
effect
vaccin
approach
particular
viru
famili
togeth
modern
develop
design
approach
may
significantli
shorten
time
need
prepar
vaccin
field
test
set
new
pandem
threat
